{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:46:56Z","timestamp":1762876016801},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0198184","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T17:40:05Z","timestamp":1527874805000},"page":"e0198184","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice"],"prefix":"10.1371","volume":"13","author":[{"given":"Fabian","family":"Depr\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasra","family":"Aboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulgabar","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"ref1","first-page":"329","article-title":"Splenectomy as a therapeutic measure in thrombocytopenic purpura haemorhagica","volume":"42","author":"A.O Whipple","year":"1926","journal-title":"Surgery, Gynecology & Obstetrics"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/archinte.1951.03810090041004","article-title":"Effect of corticotrophin and cortisone on the blood in various disorders in man","volume":"88","author":"MM Wintrobe","year":"1951","journal-title":"AMA Arch Intern Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2015.08.001","article-title":"The History of Cortisone Discovery and Development","volume":"42","author":"CM Burns","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/MOH.0b013e3282b9748f","article-title":"Immune thrombocytopenic purpura in adults","volume":"14","author":"B Godeau","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"P Imbach","year":"1981","journal-title":"Lancet"},{"key":"ref6","first-page":"81","article-title":"High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood","volume":"36","author":"P Imbach","year":"1981","journal-title":"Helv Paediatr Acta"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0140-6736(83)90175-7","article-title":"Effect of intravenous immunoglobulin in immune thrombocytopenia","volume":"2","author":"A Salama","year":"1983","journal-title":"Lancet"},{"key":"ref8","first-page":"99","article-title":"A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"MN Saleh","year":"2000","journal-title":"Semin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"G Cheng","year":"2011","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"MN Saleh","year":"2013","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"DJ Kuter","year":"2008","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"DJ Kuter","year":"2010","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14728214.2017.1294158","article-title":"Emerging drugs for immune thrombocytopenia (ITP)","volume":"22","author":"A Salama","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia","volume":"128","author":"A Cuker","year":"2016","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s12325-015-0251-z","article-title":"Current Management of Primary Immune Thrombocytopenia","volume":"32","author":"D Provan","year":"2015","journal-title":"Adv Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/bjh.13415","article-title":"Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012","volume":"170","author":"M Michel","year":"2015","journal-title":"Br J Haematol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e27350","DOI":"10.1371\/journal.pone.0027350","article-title":"Advances in ITP\u2014therapy and quality of life\u2014a patient survey","volume":"6","author":"AC Matzdorff","year":"2011","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1586\/ehm.10.76","article-title":"Current treatment options for primary immune thrombocytopenia","volume":"4","author":"A Salama","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000442769","article-title":"Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995\u20132014","volume":"39","author":"R Weide","journal-title":"Oncol Res Treat. 2016"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1445-5994.2012.02740.x","article-title":"Presentation and outcome of idiopathic thrombocytopenic purpura in a single Australian centre","volume":"42","author":"PY Choi","year":"2012","journal-title":"Intern Med J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1592\/phco.30.7.666","article-title":"Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag","volume":"30","author":"JD Chouhan","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-140-3-200402030-00012","article-title":"Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review","volume":"140","author":"SK Vesely","year":"2004","journal-title":"Ann Intern Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"D Provan","year":"2010","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"C Neunert","year":"2011","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000356910","article-title":"Immune thrombocytopenia\u2014onkopedic guidelines update: recommendations of a joint working group of the DGHO, \u00d6GHO, SGH + SSH and GPOH","volume":"37","author":"A Matzdorff","year":"2010","journal-title":"Oncol Res Treat"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00277-016-2665-3","article-title":"S\u00e1nchez-Gonzalez B et al. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines","volume":"95","author":"ML Lozano","year":"2016","journal-title":"Ann Hematol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2011-12-309153","article-title":"How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment","volume":"120","author":"W Ghanima","year":"2012","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0609.2009.01361.x","article-title":"Treatment practices in adults with chronic immune thrombocytopenia\u2014a European perspective","volume":"84","author":"F Rodeghiero","year":"2010","journal-title":"Eur J Haematol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.25961","article-title":"Multicenter Cohort Study Comparing U.S. Management of Inpatient Pediatric Immune Thrombocytopenia to Current Treatment Guidelines","volume":"63","author":"CM Witmer","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1203\/00006450-200009000-00019","article-title":"Ethnicity and environment may affect the phenotype of immune thrombocytopenic purpura in children","volume":"48","author":"T K\u00fchne","year":"2000","journal-title":"Pediatr Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12185-011-0894-8","article-title":"Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region","volume":"94","author":"LH Lee","year":"2011","journal-title":"Int J Hematol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adultsand children: report from an international working group","volume":"113","author":"F Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000446195","article-title":"Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and\/or Cause Adverse Reactions: Results from One Hand","volume":"43","author":"F Depr\u00e9","year":"2016","journal-title":"Transfus Med Hemother"},{"key":"ref34","first-page":"1","article-title":"Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review","volume":"25","author":"F Depr\u00e9","year":"2017","journal-title":"Blood Transfus"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/pbc.21006","article-title":"Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia","volume":"47","author":"O Meyer","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1600-0609.2004.00244.x","article-title":"Efficacy and safety of anti-D given by subcutaneous injection to patients with autoimmune thrombocytopenia","volume":"73","author":"O Meyer","year":"2004","journal-title":"Eur J Haematol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/pbc.22248","article-title":"Subcutaneous anti-D treatment of idiopathic thrombocytopenic purpura in children","volume":"53","author":"M Kjaersgaard","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V89.8.2689","article-title":"Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients","volume":"89","author":"A Scaradavou","year":"1997","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1182\/blood-2016-03-704734","article-title":"Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia","volume":"128","author":"M Mah\u00e9vas","year":"2016","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2010-10-312819","article-title":"Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study","volume":"117","author":"M N\u00f8rgaard","year":"2011","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9343(99)80342-8","article-title":"Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"R Stasi","year":"1995","journal-title":"Am J Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-0034-1544001","article-title":"Can immune thrombocytopenia be cured with medical therapy?","volume":"41","author":"A Cuker","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-140-3-200402030-00012","article-title":"Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review","volume":"140","author":"SK Vesely","year":"2004","journal-title":"Ann Intern Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3324\/haematol.2012.075648","article-title":"Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years","volume":"98","author":"N Vianelli","year":"2013","journal-title":"Haematologica"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/vox.12467","article-title":"New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia","volume":"112","author":"B Mayer","year":"2017","journal-title":"Vox Sang"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1182\/blood-2011-03-340166","article-title":"Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in aromiplostim compassionate-use program","volume":"118","author":"M Khellaff","year":"2011","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia","volume":"118","author":"JB Bussell","year":"2011","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"DJ Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.7326\/0003-4819-126-4-199702150-00007","article-title":"Therapy for Adults with Refractory Chronic Immune Thrombocytopenic Purpura","volume":"126","author":"R McMillan","year":"1997","journal-title":"Ann Intern Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2141.2008.07275.x","article-title":"Refractory immune thrombocytopenic purpura: current strategies for investigation and management","volume":"143","author":"B Psaila","year":"2008","journal-title":"Br J Haematol."},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/j.1538-7836.2006.02013.x","article-title":"Management of patients with refractory immune thrombocytopenic purpura","volume":"4","author":"JN George","year":"2006","journal-title":"J Thromb Haemost"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"JE Portielje","year":"2001","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000449038","article-title":"Is Autoimmune Thrombocytopenia Itself the Primary Disease in the Presence of Second Diseases Data from a Long-Term Observation","volume":"44","author":"N Aboud","year":"2017","journal-title":"Transfus Med Hemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0198184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T00:32:20Z","timestamp":1571445140000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0198184"}},"subtitle":[],"editor":[{"given":"Gualtiero I.","family":"Colombo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0198184","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}